BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Industry & Community
Orforglipron and the Non-Peptide GLP-1: Why a Small-Molecule Approval Matters to the Peptide Research Sector
Eli Lilly's orforglipron (Foundayo) was FDA-approved in April 2026 as the first oral small-molecule GLP-1 receptor agonist — a compound that is structurally not a peptide. Its MHRA review is under way, with a potential UK marketing authorisation in late 2026. For research-procurement professionals, the distinction matters: orforglipron's approval reframes the competitive landscape for peptide-based GLP-1 manufacturing and signals where the next phase of obesity pharmacology is heading.
05 Aug 2026
Industry & Community
Samsung Biologics' $1.8 Billion PolyPeptide Bid: What the Deal Signals for Global Peptide Manufacturing Capacity
Samsung Biologics launched a CHF 1.46 billion all-cash tender offer for Swiss peptide CDMO PolyPeptide Group on 20 July 2026 — the largest-ever Korean biopharma acquisition. The move accelerates a consolidation wave in peptide contract manufacturing driven by sustained GLP-1 demand, and carries direct implications for research-procurement teams monitoring API supply-chain resilience.
31 Jul 2026
Industry & Community
Samsung Biologics Bids $1.8 Billion for Swiss Peptide CDMO PolyPeptide Group in Korea's Largest-Ever Pharma Deal
Samsung Biologics launched an all-cash public tender offer of CHF 1.46 billion ($1.8 billion) for Switzerland's PolyPeptide Group on 20 July 2026 — the largest biopharmaceutical M&A transaction in South Korean history. The deal brings a 70-year-old peptide CDMO, six GMP-certified manufacturing sites, and direct exposure to GLP-1 API demand under Samsung Biologics' roof, and signals how urgently global CDMO operators are moving to secure peptide manufacturing capacity ahead of a projected $29…
25 Jul 2026
Industry & Community
The Oral GLP-1 Race in 2026: What the Shift from Peptide Injections to Small-Molecule Pills Means for the Research Supply Chain
The MHRA approved the first oral GLP-1 tablet for weight loss in June 2026, and the FDA followed with orforglipron (Foundayo) — the first non-peptide small-molecule GLP-1 — in April. Head-to-head trial data now favour the small-molecule entrant on both glycaemic control and weight loss, raising structural questions for peptide API manufacturers and research-grade suppliers about where future demand will concentrate.
25 Jul 2026
Industry & Community
Macrocyclic Peptides: How a $1.8bn Novartis Deal and a String of Venture Rounds Signalled the Modality's Arrival in 2026
Macrocyclic peptides — ring-shaped molecules that sit between small molecules and biologics — have attracted more than $500 million in venture funding and several billion dollars in licensing deals in the first half of 2026. The capital surge reflects growing conviction that AI-assisted platform chemistry can now reliably produce oral macrocycles against targets that have resisted conventional drug design. Research procurement teams sourcing peptide compounds should understand what is driving…
10 Jul 2026
Industry & Community
The Oral GLP-1 Race in 2026: What the Wegovy Pill, Foundayo, and the NICE July Appraisal Mean for UK Research Procurement
The MHRA approved oral semaglutide (Wegovy pill) in June 2026 and a NICE committee is due to meet this month to assess orforglipron (Foundayo) for NHS use. With two mechanistically distinct oral GLP-1 agents now in or approaching the UK market, procurement teams need to understand the clinical differentiation, supply implications, and regulatory timelines that will shape research and clinical access.
07 Jul 2026
Industry & Community
The Oral Peptide Race: How 2026's Approvals and Investment Wave Are Reshaping Peptide Drug Development
Two landmark FDA approvals in early 2026 — Eli Lilly's orforglipron (Foundayo) and Johnson & Johnson's icotrokinra (ICOTYDE) — have validated oral peptide and peptide-mimetic delivery as a commercially viable drug class. Backed by hundreds of millions in fresh venture capital, the sector is moving rapidly from injectable-only paradigms toward once-daily pills. For UK research-procurement teams, the shift has direct implications for the tools, reference compounds, and analytical standards their…
23 Jun 2026
Industry & Community
The 2026 Oral Peptide Wave: What Approved Drugs, NDA Filings and Major Funding Rounds Mean for Research Procurement
A convergence of approvals, regulatory filings and investor capital is reshaping the oral peptide landscape in 2026. From orforglipron's April FDA clearance to Merck's NDA submission for an oral macrocyclic PCSK9 inhibitor and two oversubscribed platform financing rounds, the field is advancing along lines that will directly influence which peptide classes attract the most research attention — and procurement spend — over the next three years.
12 Jun 2026
Industry & Community
Peptide Platforms Attract Record Capital: What the Parabilis $670M IPO and 2026 Investment Surge Mean for Research Procurement
Parabilis Medicines closed the largest-ever venture-backed biotech IPO on 9 June 2026, raising $670 million for its Helicon helix-shaped peptide platform. Alongside a string of peptide-focused funding rounds, the capital surge signals a structural shift in how investors view peptide drug discovery — with direct implications for supply chains, platform technologies, and procurement priorities at UK research labs.
11 Jun 2026
Industry & Community
The Macrocyclic Peptide Investment Wave: What Three Major 2026 Deals Signal for the Research Landscape
A cluster of substantial deals in early 2026 — including Novartis's $100 million upfront commitment to Unnatural Products, Syneron Bio's $150 million Series B, and AstraZeneca's ongoing $3.4 billion biobucks arrangement — marks macrocyclic peptides as the modality attracting the most concentrated institutional attention in the peptide space. For research-procurement teams, understanding what distinguishes macrocycles from conventional linear peptides, and why big pharma is now paying platform…
30 May 2026
Industry & Community
Macrocyclic Peptides Draw Wave of Institutional Capital in 2026 as Big Pharma Targets "Undruggable" Biology
A cluster of deals in early 2026 has placed macrocyclic peptides at the centre of pharmaceutical dealmaking, with Syneron Bio closing a $150 million Series B, Novartis committing up to $1.8 billion to Unnatural Products, and AstraZeneca holding a strategic stake in the macrocycle space. For research-procurement teams, the surge signals where institutional confidence in the peptide modality is moving.
15 May 2026